2-氯-1H-苯并咪唑-5-羧酸 | 933710-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-氯-1H-苯并咪唑-5-羧酸
• 英文名称: 2-chloro-1H-benzo[d]imidazole-5-carboxylic acid
• 英文别名: 2-chloro-3H-benzimidazole-5-carboxylic acid
• CAS: 933710-78-2
• 化学式: C₈H₅ClN₂O₂
• mdl: MFCD11044637
• 分子量: 196.593
• InChiKey: QNLZXSMWOUVWPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-氯-1H-苯并咪唑-5-羧酸 在 一水合肼 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 3.0h， 以0.1 g的产率得到2-肼基-1H-苯并咪唑-5-羧酸
  参考文献：
  名称：

  [EN] COMPOUNDS AS RAS INHIBITORS AND USE THEREOF
  [FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE RAS ET LEUR UTILISATION

  摘要：

  描述了一个式(Ia)或(Ib)的化合物，或其药用盐，其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用相同化合物的方法。

  公开号：

  WO2019055540A1
• 作为产物：
  描述：

  3,4-二氨基苯甲酸甲酯 在 水 、 sodium hydroxide 、 三氯氧磷 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.0h， 生成 2-氯-1H-苯并咪唑-5-羧酸
  参考文献：
  名称：

  [EN] COMPOUNDS AS RAS INHIBITORS AND USE THEREOF
  [FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE RAS ET LEUR UTILISATION

  摘要：

  描述了一个式(Ia)或(Ib)的化合物，或其药用盐，其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用相同化合物的方法。

  公开号：

  WO2019055540A1

文献信息

• [EN] INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY<br/>[FR] INHIBITEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：PRAXIS BIOTECH LLC

  公开号：WO2020252205A1

  公开（公告）日：2020-12-17

  The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.

  本公开涉及通常可用作抑制综合应激反应（ISR）途径的治疗剂。
• ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE
  申请人：Eckhardt Matthias

  公开号：US20120157488A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds defined by formula I wherein the variables R 1 , R 2 , R 3 , R 4 , and m are defined as in claim 1 , possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由公式I定义的化合物，其中变量R1、R2、R3、R4和m如权利要求1所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• PIPERIDINE DERIVATIVES OR SALTS THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP2085383A1

  公开（公告）日：2009-08-05

  [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  [问题]提供一种可用于治疗钙传感受体（CaSR）参与的疾病，特别是甲状旁腺机能亢进的化合物。 [解决方法]发现一种新型哌啶衍生物，其特征在于 3 位和 4 位中的一个被氨甲基取代，另一个被芳基、杂芳基等取代，或其盐具有极好的 CaSR 激动调节作用，同时还具有极好的选择性，具有 CYP2D6 抑制作用，但有可能引起药物相互作用。基于以上所述，这种新型哌啶衍生物可作为治疗剂用于治疗 CaSR 参与的疾病（甲状旁腺功能亢进症、肾性骨营养不良症、高钙血症等）。
• NOVEL BENZIMIDAZOLE DERIVATIVE
  申请人：Carna Biosciences, Inc.

  公开号：EP4129406A1

  公开（公告）日：2023-02-08

  A benzimidazole derivative represented by formula (I) (wherein A1 to A3 and R1 to R6 are as described in the description) or a pharmaceutically acceptable salt thereof, which inhibits activation of STING pathway and, therefore, which is useful as a prophylactic or therapeutic medicine for inflammatory diseases, autoimmune diseases, cancer, etc.

  一种苯并咪唑衍生物，由式(I)表示（其中A1至A3和R1至R6如说明书中所述），或其药学上可接受的盐，其抑制STING通路的激活，因此作为预防或治疗炎症性疾病、自身免疫性疾病、癌症等的药物是有用的。
• Structural Development Studies of Pyrazoloketone-Derived Acetyl-CoA Carboxylase Inhibitors
  作者：Takao Yamaguchi、Shogo Okazaki、Taki Sakai、Minoru Ishikawa、Yuichi Hashimoto

  DOI：10.3987/com-16-s(s)30

  日期：——

  Acetyl-CoA carboxylase (ACC) plays a key role in fatty acid homeostasis in humans, and inhibitors of ACC are expected to inhibit fatty acid biosynthesis and to activate fatty acid beta-oxidation. Therefore, they are considered to be candidates for treatment of metabolic syndrome and related diseases. In this context, an upstream kinase of ACC, adenosine monophosphate-activated protein kinase (AMPK), has also recently emerged as a potential therapeutic target, because it phosphorylates and inactivates ACC. Here, we designed a fused molecule consisting of a pyrazoloketone-type ACC inhibitor and a recently discovered AMPK activator, aiming to develop a novel combined ACC inhibitor/AMPK activator to regulate fatty acid levels. The designed compound was prepared through a convergent synthetic route. This compound and its methyl ester analogue showed potent ACC2-inhibitory activity with IC50 values of 8.8 and 1.3 mu M, respectively. Exomethylene derivatives, obtained from an unexpected side reaction during deprotection, also exhibited ACC2-inhibitory activity.